US2007224270A1PendingUtilityA1

Nicotinic Acid Compositions For Treating Hyperlipidemia and Related Methods Therefor

63
Individually held — no corporate assignee on recordPriority: Sep 20, 1993Filed: Jun 4, 2007Published: Sep 27, 2007
Est. expirySep 20, 2013(expired)· nominal 20-yr term from priority
Inventors:David J. Bova
A61P 7/00A61K 9/2054A61P 3/10A61P 3/06A61K 9/2077A61K 31/455A61K 31/44A61K 9/2027
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyper lipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.

Claims

exact text as granted — not AI-modified
1 . (canceled)  
     
     
         2 . (canceled)  
     
     
         3 . (canceled)  
     
     
         4 . (canceled)  
     
     
         5 . (canceled)  
     
     
         6 . (canceled)  
     
     
         7 . (canceled)  
     
     
         8 . (canceled)  
     
     
         9 . (canceled)  
     
     
         10 . (canceled)  
     
     
         11 . (canceled)  
     
     
         12 . (canceled)  
     
     
         13 . A sustained release antihyperlipidemia composition comprising: 
 about 500 mg to about 3000 mg of nicotinic acid and a pharmaceutically acceptable carrier,    wherein the composition is administered to a hyperlipidemic after food once per day, and further wherein the composition reduces the total cholesterol, LDL cholesterol, triglycerides and Lp(a) of the hyperlipidemic, and further wherein the composition significantly increases the HDL cholesterol of the hyperlipidemic.    
     
     
         14 . The composition according to  claim 13 , wherein the composition is dosed with from about 250 parts to about 3000 parts by weight of nicotinic acid.  
     
     
         15 . The composition according to  claim 13 , wherein the release rate of said nicotinic acid is from about 2.0% per hour to about 25% per hour.  
     
     
         16 . The composition according to  claim 13 , wherein the nicotinic acid is dosed in the form of a tablet prepared by formulating the nicotinic acid with from about 5% to about 50% parts by weight of hydroxypropyl methylcellulose per 100 parts by weight of tablet.  
     
     
         17 . The composition according to  claim 13 , wherein the nicotinic acid is dosed in a form of a tablet containing from about 1 to about 4 parts by weight binder per 100 parts by weight of tablet.  
     
     
         18 . The composition according to  claim 17 , wherein the binder is a polymer having the repeating polymerization unit 1-ethenyl-2-pyrrolidone.  
     
     
         19 . The composition according to  claim 13 , wherein the nicotinic acid is dosed in a form of a tablet comprising from about 0.5 to about 2.5 parts by weight of a lubricating agent per 100 parts by weight of tablet.  
     
     
         20 . The composition according to  claim 19 , wherein the lubricating agent is selected from the group consisting of stearic acid and magnesium stearate.  
     
     
         21 . The composition according to  claim 13 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         22 . The composition of  claim 13 , wherein the composition contains about 500 mg nicotinic acid.  
     
     
         23 . The composition according to  claim 13 , wherein the composition contains about 750 mg nicotinic acid.  
     
     
         24 . The composition according to  claim 13 , wherein the composition contains about 1000 mg nicotinic acid.  
     
     
         25 . The composition according to  claim 13 , wherein the composition contains about 1500 mg nicotinic acid.  
     
     
         26 . The composition according to  claim 13 , wherein the composition contains about 2000 mg nicotinic acid.  
     
     
         27 . The composition according to  claim 13 , wherein the composition contains about 3000 mg nicotinic acid.  
     
     
         28 . The composition according to  claim 22 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         29 . The composition according to  claim 23 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         30 . The composition according to  claim 24 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         31 . The composition according to  claim 25 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         32 . The composition according to  claim 26 , wherein the nicotinic acid is dosed in the evening or at night.  
     
     
         33 . The composition according to  claim 27 , wherein the nicotinic acid is dosed in the evening or at night.

Join the waitlist — get patent alerts

Track US2007224270A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.